Abcam, ab185289, Anti-Malignant fibrous histiocytoma antibody

Size: 100µL
Rabbit Polyclonal Malignant fibrous histiocytoma antibody. Suitable for IHC-P, WB, ICC/IF and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Recombinant Fragment Protein within Human MFHAS1 aa 950-1050.
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:ICC/IF, IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Recombinant Fragment Protein within Human MFHAS1 aa 950-1050. The exact immunogen used to generate this antibody is proprietary information.Q9Y4C4

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Storage buffer-pH: 7.2Preservative: 0.02% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Malignant fibrous histiocytoma (MFH) also known as pleomorphic undifferentiated sarcoma is a soft tissue sarcoma originating from fibroblasts and histiocytes. Mechanically MFH involves abnormal proliferation and differentiation of these cells leading to tumor formation. It generally expresses in adult skeletal muscle tissues and retroperitoneal regions. The mass of MFH tumors can vary significantly depending on the growth stage and specific anatomical location involved.
Biological function summary
The abnormal cell behavior in malignant histiocytomas disrupts tissue architecture leading to invasive growth. The tumor microenvironment supports the survival and proliferation of tumor cells influencing angiogenesis and immune evasion. It does not usually form a well-defined complex instead presenting as a diverse group of cells with various differentiation patterns within the tumor mass.
Pathways
Malignant histiocytomas engage with several signaling and growth pathways. One major pathway is the PI3K/AKT pathway which regulates cell survival. Alongside the mTOR pathway plays a role in cell growth and protein synthesis. Proteins like AKT1 and mTOR themselves are related components within these pathways contributing to the aggressive behavior and survival advantage that the tumor cells sustain.
Malignant histiocytoma associates with aggressive soft tissue sarcomas and can metastasize impacting survival rates negatively. It is related to diseases like liposarcoma with both sharing alterations in similar pathways. Furthermore MFH has connections with tumors displaying overactive expression of the protein p53 which when mutated loses its normal function leading to uncontrollable cell growth.